The combinations of oncogenic KrasG12D with Trp53, Cdkn2a or Smad4 mutations successfully delineated the role of these genes in PC and showed that the synergistic effects of inactivating mutations of tumor suppressor genes with KrasG12D on PC progression depend on the specific inactivating mutation [8–11]. This evidence concerns the gene CDKN2A and neoplasm.